Maurice Zauderer net worth and biography

Maurice Zauderer Biography and Net Worth

Maurice Zauderer, Ph.D. has served as our President and Chief Executive Officer and a member of our board of directors since our inception in April 2001. Prior to founding the company, Dr. Zauderer was an Associate Professor at the University of Rochester and has also held senior faculty positions at Columbia University. During his academic career, Dr. Zauderer held the position of visiting scientist at the Laboratory of Cell Biology, the Ontario Cancer Institute and the National Cancer Institute. Dr. Zauderer received a B.S. in Physics from Yeshiva University and a Ph.D. in Cell Biology from the Massachusetts Institute of Technology.

What is Maurice Zauderer's net worth?: The estimated net worth of Maurice Zauderer is at least $5,865.60 as of October 3rd, 2023. Dr. Zauderer owns 1,222 shares of Vaccinex stock worth more than $5,866 as of April 18th. This net worth estimate does not reflect any other investments that Dr. Zauderer may own. Additionally, Dr. Zauderer receives a salary of $400,700.00 as CEO at Vaccinex. Learn More about Maurice Zauderer's net worth.
How old is Maurice Zauderer?: Dr. Zauderer is currently 78 years old. There are 4 older executives and no younger executives at Vaccinex. Learn More on Maurice Zauderer's age.
What is Maurice Zauderer's salary?: As the CEO of Vaccinex, Inc., Dr. Zauderer earns $400,700.00 per year. Learn More on Maurice Zauderer's salary.
How do I contact Maurice Zauderer?: The corporate mailing address for Dr. Zauderer and other Vaccinex executives is 1895 MOUNT HOPE AVENUE, ROCHESTER NY, 14620. Vaccinex can also be reached via phone at (585) 271-2700 and via email at [email protected]. Learn More on Maurice Zauderer's contact information.
Has Maurice Zauderer been buying or selling shares of Vaccinex?: Maurice Zauderer has not been actively trading shares of Vaccinex within the last three months. Most recently, on Tuesday, October 3rd, Maurice Zauderer bought 357 shares of Vaccinex stock. The stock was acquired at an average cost of $13.02 per share, with a total value of $4,648.14. Following the completion of the transaction, the chief executive officer now directly owns 1,222 shares of the company's stock, valued at $15,910.44. Learn More on Maurice Zauderer's trading history.
Who are Vaccinex's active insiders?: Vaccinex's insider roster includes Jacob Frieberg (Director), and Maurice Zauderer (CEO). Learn More on Vaccinex's active insiders.
Are insiders buying or selling shares of Vaccinex?: During the last year, Vaccinex insiders bought shares 2 times. They purchased a total of 214,642 shares worth more than $3,004,638.14. During the last year, insiders at the sold shares 1 times. They sold a total of 224 shares worth more than $2,257.92. The most recent insider tranaction occured on December, 26th when Director Strydonck Gerald E. Van sold 224 shares worth more than $2,257.92. Insiders at Vaccinex own 51.5% of the company. Learn More about insider trades at Vaccinex.
Information on this page was last updated on 12/26/2023.

Maurice Zauderer Insider Trading History at Vaccinex

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/3/2023	Buy	357	$13.02	$4,648.14	1,222
1/27/2022	Buy	8,580	$233.10	$1,999,998.00
1/23/2020	Buy	467	$1,476.30	$689,432.10
7/30/2019	Buy	875	$856.80	$749,700.00

Maurice Zauderer Buying and Selling Activity at Vaccinex

Vaccinex Company Overview

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. Its Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. It has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. The company was incorporated in 2001 and is headquartered in Rochester, New York.

Today's Range

Now: $4.80

$4.43

$5.18

50 Day Range

MA: $8.11

$4.76

$12.25

2 Week Range

Now: $4.80

$4.43

$100.80

Volume

11,069 shs

Average Volume

11,855 shs

Market Capitalization

$5.90 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.74

Biden’s $374B Giveaway Into This Sector

From DTI | Ad

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

Maurice Zauderer Biography and Net Worth

What is Maurice Zauderer's net worth?

How old is Maurice Zauderer?

What is Maurice Zauderer's salary?

How do I contact Maurice Zauderer?

Has Maurice Zauderer been buying or selling shares of Vaccinex?

Who are Vaccinex's active insiders?

Are insiders buying or selling shares of Vaccinex?